ADVI’s Lindsay Bealor Greenleaf told BioWorld that whether the launch interchangeable insulin biosimilars will result in lower costs for patients will be decided by PBMs.

In The News,

Mar 15 2022

ADVI’s Lindsay Bealor Greenleaf told BioWorld that whether the launch interchangeable insulin biosimilars will result in lower costs for patients will be decided by PBMs.

March 14, 2022, ADVI’s Lindsay Bealor Greenleaf told BioWorld that whether the launch interchangeable insulin biosimilars will result in lower costs for patients will be decided by PBMs. Read the full article here.